Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Rightmove keeps FY targets but warns growth will slow in H2

(Sharecast News) - Property portal operator Rightmove has reiterated its full-year guidance after a "strong" first half, in which revenues and operating profits both rose by a tenth, but warned that growth will slow slightly in the second half. Revenues totalled £211.7m during the six months to 30 June, up from £192.1m a year earlier, despite total memberships rising just 1%, as agents and developers upgraded packages and purchased incremental products, Rightmove said.

Average revenues per advertiser grew by £112 to £1,609, helped by particular strength in the new homes market.

Meanwhile, the company boasted sustained traffic growth, with the total time spent on the platform up 10% at 9.1bn minutes - its second-highest on record.

Operating profits were up 10% at £145.4m, as the underlying operating profit margin inched higher to 71% from 70% last year.

Rightmove also raised its interim dividend by 9% to 4.05p per share.

Looking ahead, the company said that property end-market trends "remain supportive for our partners' businesses", with further cuts to interest rates expected before the end of the year, and the lowest two-year fixed mortgage rate down 88 basis points compared with last year at 3.8%.

For the full year, Rightmove said it continues to expect revenue growth of 8-10%, but added: "H2 will see ongoing revenue growth, but following last year's record H2 we expect the year-on-year revenue growth percentage in H2 to be lower than H1."

The stock was down 2.1% at 774.6p by 0835 BST.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.